Kamel 2019.

Methods	Randomised controlled trial Duration and location of the trial: quote: "The current study was a randomized open‐labeled controlled study conducted in Assiut Women Health Hospital between April 2017 and October 2018."
Participants	Inclusion criteria: all primary and secondary infertile women less than 39 years due to anovulation due to PCOD according to Rotterdam diagnostic criteria Primary or secondary infertility. Absence of galactorrhoea Normal serum prolactin Normal Hysterosalpinography Husband has normal semen analysis Exclusion criteria: Male factor infertility, tubal factor infertility Endocrinopathy as (hypothyroidism, hyperprolactinemia) BMI > 35 kg/m2 Patients with previous ovarian surgery including LOD Number of centres: single‐centre trial Number of women randomised: 120 Number of women analysed: 110 Number of withdrawals/exclusions/loss to follow‐up and reasons: 5 in each group respectively, lost to follow‐up Age (y): group A CC + NAC: 27.89 ± 5.92; Group B Let: 27.84 ± 5.17 BMI (kg/m²): group A CC + NAC: 28.67 ± 3.0; Group B Let: 27.28 ± 3.43 Duration of infertility (y): Group A CC + NAC: 3.08 ± 2.17; Group B Let: 2.96 ± 1.75 Country: Egypt
Interventions	Group A: quote: "CC 100 mg +NAC 600 mg started from third day of cycle for 5 days." Group B: quote: "Lertozole 5 mg alone started from third day of cycle for 5 days."
Outcomes	Primary outcome: ovulation rate in both groups Secondary outcomes: mid‐cyclic endometrial thickness, OHSS, clinical pregnancy and miscarriage rates
Notes	Ethical approval: yes, quote: "The Institutional Ethical Review board approved the study." Informed consent: yes, quote: "All patients signed informed written consent before participation in the study." Source of funding: not stated Conflicts of interest: not stated Power calculation: not stated Trial was moved to awaiting classification as there are concerns about the validity of the trial data.